Title | BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Swaminathan, Srividya, Huang ChuanXin, Geng Huimin, Chen Zhengshan, Harvey Richard, Kang Huining, Ng Carina, Titz Björn, Hurtz Christian, Sadiyah Mohammed Firas, Nowak Daniel, Thoennissen Gabriela B., Rand Vikki, Graeber Thomas G., H Koeffler Phillip, Carroll William L., Willman Cheryl L., Hall Andrew G., Igarashi Kazuhiko, Melnick Ari, and Müschen Markus |
Journal | Nat Med |
Volume | 19 |
Issue | 8 |
Pagination | 1014-22 |
Date Published | 2013 Aug |
ISSN | 1546-170X |
Keywords | Animals, Basic-Leucine Zipper Transcription Factors, Cell Death, Cell Differentiation, Cell Survival, Cell Transformation, Neoplastic, DNA-Binding Proteins, Gene Deletion, Gene Expression Regulation, Leukemic, Green Fluorescent Proteins, Immunoglobulin mu-Chains, Mice, Molecular Sequence Data, PAX5 Transcription Factor, Pre-B Cell Receptors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cells, B-Lymphoid, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-myc, RNA, Messenger, STAT5 Transcription Factor, Treatment Outcome, Tumor Suppressor Protein p53, V(D)J Recombination |
Abstract | <p>The B cell-specific transcription factor BACH2 is required for affinity maturation of B cells. Here we show that Bach2-mediated activation of p53 is required for stringent elimination of pre-B cells that failed to productively rearrange immunoglobulin VH-DJH gene segments. After productive VH-DJH gene rearrangement, pre-B cell receptor signaling ends BACH2-mediated negative selection through B cell lymphoma 6 (BCL6)-mediated repression of p53. In patients with pre-B acute lymphoblastic leukemia, the BACH2-mediated checkpoint control is compromised by deletions, rare somatic mutations and loss of its upstream activator, PAX5. Low levels of BACH2 expression in these patients represent a strong independent predictor of poor clinical outcome. In this study, we demonstrate that Bach2(+/+) pre-B cells resist leukemic transformation by Myc through Bach2-dependent upregulation of p53 and do not initiate fatal leukemia in transplant-recipient mice. Chromatin immunoprecipitation sequencing and gene expression analyses carried out by us revealed that BACH2 competes with BCL6 for promoter binding and reverses BCL6-mediated repression of p53 and other cell cycle checkpoint-control genes. These findings identify BACH2 as a crucial mediator of negative selection at the pre-B cell receptor checkpoint and a safeguard against leukemogenesis.</p> |
DOI | 10.1038/nm.3247 |
Alternate Journal | Nat Med |
PubMed ID | 23852341 |
PubMed Central ID | PMC3954721 |
Grant List | R01 CA157644 / CA / NCI NIH HHS / United States R01 CA172558 / CA / NCI NIH HHS / United States U01 CA157937 / CA / NCI NIH HHS / United States R01CA169458 / CA / NCI NIH HHS / United States R01CA172558 / CA / NCI NIH HHS / United States R01CA139032 / CA / NCI NIH HHS / United States R01 CA137060 / CA / NCI NIH HHS / United States R01CA137060 / CA / NCI NIH HHS / United States R01 CA169458 / CA / NCI NIH HHS / United States R01 CA139032 / CA / NCI NIH HHS / United States R01CA157644 / CA / NCI NIH HHS / United States |